ArticleJournal of veterinary internal medicine2019
Efficacy of long-term oral telmisartan treatment in cats with hypertension: Results of a prospective European clinical trial.
Article in Journal of veterinary internal medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- 2026 iCatCare consensus guidelines on the diagnosis and management of chronic kidney disease in cats.Journal of feline medicine and surgery · 2026Guideline
- Circulating renin-angiotensin-aldosterone system markers in cats with non-hypertensive chronic kidney disease or systemic arterial hypertension.Journal of veterinary internal medicine · 2026Article
- Clinical therapeutics in feline medicine: updates for old and new drugs.Journal of feline medicine and surgery · 2025Review
- Post hoc comparison of the intrarenal and circulating renin-angiotensin(-aldosterone) systems in cats with ischemia-induced chronic kidney disease.Physiological reports · 2025Article
- Description of unilateral kidney embolism and contralateral nephrectomy as a less invasive remnant kidney model in cats; a proof-of-concept study.Animal models and experimental medicine · 2025Article
- Use of amlodipine in the treatment of cats with systemic hypertension in Japan.The Journal of veterinary medical science · 2024Article
- Evaluation of Renin-Angiotensin-Aldosterone System Components and Enzymes in Systemically Hypertensive Cats Receiving Amlodipine.Animals : an open access journal from MDPI · 2023Article
- Clinical management of feline chronic kidney disease in Portugal: a questionnaire-based study.Journal of feline medicine and surgery · 2023Article
- Manifestations of hypertensive encephalopathy in cats.Journal of feline medicine and surgery · 2023Article
- The standards of reporting trials in pets (PetSORT): Explanation and elaboration.Frontiers in veterinary science · 2023Article
- Single-dose pharmacokinetics of telmisartan oral solution and effect of feeding in dogs.Journal of veterinary pharmacology and therapeutics · 2023Article
- Effects of plasma aldosterone concentration and treatment with eplerenone on the survival of cats with chronic kidney disease.The Canadian veterinary journal = La revue veterinaire canadienne · 2022Article
- The Feline Cardiomyopathies: 2. Hypertrophic cardiomyopathy.Journal of feline medicine and surgery · 2021Article
- Reliability of detecting fundus abnormalities associated with systemic hypertension in cats assessed by veterinarians with and without ophthalmology specialty training.Journal of feline medicine and surgery · 2021Article
- Feline comorbidities: The intermingled relationship between chronic kidney disease and hypertension.Journal of feline medicine and surgery · 2021Review
- Treatment of proteinuria in dogs with telmisartan: A retrospective study.Journal of veterinary internal medicine · 2021Article
- Effect of telmisartan, angiotensin-converting enzyme inhibition, or both, on proteinuria and blood pressure in dogs.Journal of veterinary internal medicine · 2021Article
- Effect of angiotensin receptor blockers and angiotensin-converting enzyme 2 on plasma equilibrium angiotensin peptide concentrations in cats with heart disease.Journal of veterinary internal medicine · 2021Article
- Aldosterone and the mineralocorticoid receptor in renal injury: A potential therapeutic target in feline chronic kidney disease.Journal of veterinary pharmacology and therapeutics · 2020Review
- Safety and efficacy of orally administered telmisartan for the treatment of systemic hypertension in cats: Results of a double-blind, placebo-controlled, randomized clinical trial.Journal of veterinary internal medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 5 countries.
Funding
Abstract
backgroundEfficacy of telmisartan in treating hypertension (HT) in cats has not been largely investigated.
objectiveTelmisartan oral solution effectively controls systolic arterial blood pressure (SABP) in hypertensive cats. ANIMALS: Two-hundred eighty-five client-owned cats with systemic HT.
methodsProspective, multicenter, placebo-controlled, randomized, double-blinded study. Hypertensive cats diagnosed with SABP ≥160 mmHg and ≤200 mmHg without target-organ-damage were randomized (2 : 1 ratio) to receive 2 mg/kg telmisartan or placebo q24 PO. A 28-day efficacy phase was followed by a 120-day extended use phase. Efficacy was defined as significant difference in mean SABP reduction between telmisartan and placebo on Day 14 and group mean reduction in SABP of > 20 mmHg by telmisartan on Day 28 compared to baseline.
resultsTwo-hundred fifty-two cats completed the efficacy and 144 cats the extended use phases. Mean SABP reduction at Day 14 differed significantly between groups (P < .001). Telmisartan reduced baseline SABP of 179 mmHg by 19.2 (95% confidence interval [CI]: 15.92-22.52) and 24.6 (95% CI: 21.11-28.14) mmHg at Days 14 and 28. The placebo group baseline SABP of 177 mmHg was reduced by 9.0 (95% CI: 5.30-12.80) and 11.4 (95% CI: 7.94-14.95) mmHg, respectively. Of note, 52% of telmisartan-treated cats had SABP <150 mmHg at Day 28. Mean SABP reduction by telmisartan in severe (≥180 mmHg) and moderate HT (160-179 mmHg) was comparable and persistent over time. CONCLUSIONS AND CLINICAL IMPORTANCE: Telmisartan solution (PO) was effective in reducing SABP in hypertensive cats with SABP ≥160 mmHg and ≤200 mmHg.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.